Evofem Biosciences Reports Record 2025 Results: Turns Profitable, Reduces Costs, and Drives Product Expansion

Key Highlights from Evofem’s 2025 Financial Report

• Net Sales Surpass \$20 Million: Evofem achieved record net sales of \$20.2 million for full year 2025—its fifth consecutive year of sales growth—driven primarily by its flagship contraceptive product, PHEXXI®.
• First Full-Year Profitability: Income from operations rose sharply to \$3.4 million in 2025, compared to a loss of \$7.7 million in 2024. Net income attributable to common stockholders was \$0.3 million (or \$0.00 per share), a significant improvement from a net loss of \$9.0 million (or \$0.11 per share) in the prior year.
• Massive Cost Reductions: Operating expenses fell by 38% year-over-year, totaling \$16.8 million (down from \$27.0 million in 2024). This reduction was aided by a \$5.6 million gain from settling trade payables, and a \$1.9 million non-cash gain related to changes in contingent royalty liabilities after the expiration of the Rush patent.
• Growth in SOLOSEC® Sales: SOLOSEC®, acquired in July 2024 and relaunched in late 2024, contributed a full year of revenue for the first time in 2025, supporting the company’s top-line growth.
• Fourth Quarter Strength: Q4 2025 net sales reached \$9.6 million, up 35% from \$7.1 million a year earlier. Q4 income from operations was \$3.3 million, turning around from a \$1.0 million operating loss in Q4 2024. Net income for the quarter was \$2.8 million (\$0.02 per basic share).

Strategic and Operational Updates

• Cost of Goods Sold (COGS) Initiatives: Evofem launched programs targeting 55-60% reductions in manufacturing costs for both PHEXXI and SOLOSEC. If successful, these cost improvements could meaningfully enhance margins and support future profitability.
• International Expansion: The Emirates Drug Establishment (EDE) issued favorable pricing certificates for PHEXXI, marking a key step toward anticipated regulatory approval in the United Arab Emirates. EDE review of the SOLOSEC application is also underway, potentially opening new markets.
• Clinical Progress: Patient recruitment is ongoing in a key NIH-funded Phase 4 trial comparing SOLOSEC (single-dose) to metronidazole (multi-dose) for the treatment of Trichomonas vaginalis in both men and women. The study aims to show that SOLOSEC reduces repeat infection rates and is more cost-effective, supporting future product positioning and reimbursement.

Key Financial Details for Investors

• Revenue Drivers: The 4% year-over-year sales growth was powered by higher PHEXXI wholesale average cost (WAC), improved gross-to-net ratio, and the first full year of SOLOSEC sales.
• Expense Management:
  • Research and development expenses fell by \$5.3 million, aided by settlements of trade payables and accrued liabilities.
  • General and administrative expenses were cut by \$4.2 million.
  • One-time \$1.9 million gain from the Rush patent expiration and related royalty liability adjustment.
  • Selling and marketing expenses rose modestly (\$0.5 million) due to a full year of SOLOSEC commercialization.
• Q4 Performance:
  • Q4 net sales up 35% to \$9.6 million, driven by higher PHEXXI pricing and sales volumes.
  • Operating expenses dropped to \$6.2 million (vs. \$8.1 million in Q4 2024).
  • Net income of \$2.8 million in Q4 2025 (vs. a \$3.0 million loss in Q4 2024).

What Shareholders Must Know: Potential Price-Moving Factors

• First Profitable Year: Evofem’s transition to profitability is a key milestone that could positively impact investor sentiment and share value.
• Cost Reduction Initiatives: If the targeted reduction in COGS is realized, it would drive higher margins and sustained profitability, which is highly price-sensitive.
• International Expansion: Progress toward regulatory approvals in the UAE for both PHEXXI and SOLOSEC creates a pathway for new revenue streams and further growth.
• Phase 4 Clinical Trial: Success in the NIH-funded trial would support a stronger clinical profile and reimbursement case for SOLOSEC, potentially expanding its market share.
• Risks and Liquidity: Despite the turnaround, Evofem highlights ongoing capital constraints, limited cash resources, dependency on new capital or business development, and the nonrecurring nature of some recent gains (such as the settlement and patent-related royalty adjustments). Investors should closely monitor future capital-raising efforts and regulatory progress.

About Evofem Biosciences

Evofem Biosciences is a San Diego-based pharmaceutical company with two FDA-approved sexual and reproductive health products:

• PHEXXI®: The first and only hormone-free, on-demand prescription contraceptive vaginal gel.
• SOLOSEC® (secnidazole): A one-dose oral antibiotic for bacterial vaginosis (BV) and trichomoniasis in people aged 12 and older.

Both products are registered trademarks of Evofem Biosciences, Inc.

Investor Contact

[email protected]
[email protected]

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements involve risks and uncertainties, including but not limited to, capital constraints, regulatory approval timelines, and market demand. Investors should review Evofem’s SEC filings and consult their financial advisor before making investment decisions. The author does not assume any responsibility for investment actions taken based on this summary.

View Evofem Biosciences, Inc. Historical chart here